Sangamo planning follow-on

Sangamo BioSciences Inc. (NASDAQ:SGMO) proposed a follow-on late Tuesday underwritten by Lazard; JMP Securities; and Piper Jaffray. The company's lead product is SB-728-T, a cell therapy consisting of...